Other News To Note
Tuesday, February 7, 2012
Cytos Biotechnology Ltd., of Zurich, Switzerland, said its convertible bond restructuring has been approved, enabling the firm to remain a going concern while it continues searching for a sustainable strategic solution. The firm has had trouble tapping the public markets, despite reporting positive Phase II data with CYT003-QbG10 in allergic asthma and allergic rhinitis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.